Table 4. Studies reviewed for incidence of PTC, FVPTC and FN in surgically resected cases of AUS/FLUS.
| Study | Country | Study period | No. of resected AUS/FLUS | No. of cases | Incidence | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| PTC | FVPTC | FN | PTC | FVPTC | FN | |||||
| Asian | ||||||||||
| Gan 2017, (16) | Singapore | 2008–2014 | 137 | 22 | 6 | NA | 0.161 | 0.273 | NA | |
| Mao 2017, (19) | Mainland China | 2014–2015 | 121 | 42 | 1 | 8 | 0.347 | 0.024 | 0.066 | |
| Ke 2019, (21) | Mainland China | 2011–2016 | 157 | 79 | NA | NA | 0.503 | NA | NA | |
| Jan 2019, (22) | Taiwan | 2012–2016 | 367 | 183 | NA | 43 | 0.499 | NA | 0.117 | |
| Chung 2011, (25) | Korea | 2005–2010 | 166 | 109 | NA | 9 | 0.657 | NA | 0.054 | |
| Hyeon 2014, (26) | Korea | 2011–2012 | 231 | 151 | 9 | 17 | 0.654 | 0.060 | 0.074 | |
| Kim M 2017, (32) | Korea | 2011 | 722 | 471 | NA | 77 | 0.652 | NA | 0.107 | |
| Selek 2016, (48) | Turkey | 2009–2014 | 112 | 42 | NA | NA | 0.375 | NA | NA | |
| Turkyilmaz 2017, (49) | Turkey | 2011–2015 | 305 | 96 | 44 | 8 | 0.315 | 0.458 | 0.026 | |
| Non-Asian | ||||||||||
| VanderLaan 2011, (6) | USA | 2005–2009 | 199 | 86 | NA | 77 | 0.432 | NA | 0.387 | |
| Broome 2014, (69) | USA | 2009–2012 | 170 | 23 | 11 | 52 | 0.135 | 0.478 | 0.306 | |
| Ho 2014, (70) | USA | 2008–2011 | 381 | 125 | 61 | 69 | 0.328 | 0.488 | 0.181 | |
| Bernstein 2016, (87) | Canada | 2010–2013 | 187 | 85 | 63 | NA | 0.455 | 0.741 | NA | |
| Sarkis 2014, (96) | Australia | 2010–2013 | 54 | 5 | NA | 19 | 0.093 | NA | 0.352 | |
| Mileva 2018, (95) | Macedonia | 2012–2016 | 85 | 26 | 8 | 28 | 0.306 | 0.308 | 0.329 | |
AUS/FLUS, atypia of undetermined significance/follicular lesion of undetermined significance; PTC, papillary thyroid carcinoma; FVPTC, follicular variant PTC; FN, follicular neoplasm (including follicular adenoma and follicular carcinoma).